Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies

Clinical and Experimental Rheumatology

Volumn 31, Issue 6, 2013, Pages 896-903

  Munoz Beamud F ^a   Isenberg, D A ^b  

^a HOSPITAL UNIVERSITARIO JUAN RAMÓN JIMÉNEZ   (Spain)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

B cell depletion therapy; Dermatomyositis; Polymyositis; Refractory myositis; Rituximab

Indexed keywords

ANTIBIOTIC AGENT; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; TACROLIMUS;

ADULT; ANTISYNTHETASE SYNDROME; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DERMATOMYOSITIS; DETERIORATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GENERALIZED ARTHROMYALGIA; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOTHERAPY; LONG TERM CARE; LOWER RESPIRATORY TRACT INFECTION; MALE; MIDDLE AGED; MYOSITIS; MYOSITIS OVERLAP SYNDROME; POLYMYOSITIS; PRIORITY JOURNAL; RASH; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS; TIME TO TREATMENT; TREATMENT DURATION; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CREATINE KINASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOSITIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84891597826     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. DALAKAS MC, HOHLFELD R: Polymyositis and dermatomyositis. Lancet 2003; 362: 971-82.
2. SULTAN S, IOANNU Y, MOSS K et al.: Outcome in patients with inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) 2002; 43: 22-6.
3. PIPITONE N, SALVARANI C: Established and new treatments of the idiopathic inflammatory myopathies: dermatomyositis and polymyositis. Clin Exp Rheumatol 2007; 25: 896-906.
4. BROUWER R, HENGSTMAN GJ, ISENBERG DA et al.: Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001; 60: 116-23.
5. MIMORI T, IMURA Y, NAKASHIMA R et al.: Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol 2007; 19: 523-9.
6. WHELAN BR, ISENBERG DA:. mAbs in non lupus autoimmune rheumatic diseases. Curr Opin Hematol 2009; 16: 280-4.
7. DALAKAS MC: Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol 2010; 6: 129-37.
8. ARKFELD DG: The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int 2008; 28: 205-15.
9. POPA C, LEANDRO MJ, CAMBRIDGE G et al.: Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 2007; 46: 626-30.
10. LU TY, NG KP, CAMBRIDGE G et al.: A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009; 61: 482-7.
11. MAIMUDAR S, HALL SA, ZIMMERMANN B: Treatment of adult inflammatory myositis with rituximab: an emerging therapy for refractory patients. J Clin Rheumatol 2009; 15: 338-40.
12. RÍOS FERNÁNDEZ R, CALLEJAS RUBIO JL, SÁNCHEZ CANO D et al.: Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol 2009; 27: 1009-16.
13. MOK CC, HO LY, TO CH: Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol 2007; 34: 1864-8.
14. BLOM M, van den HOOGEN FH, VOERMANS NC et al.: Successful treatment with rituximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2007; 66 (Suppl. II): 202.
15. NOSS EH, HAUSNER-SYPEK DL, WEINBLATT ME: Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006; 33: 1021-6.
16. CHIAPPETTA N, STEIER J, GRUBER B: Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol 2005; 11: 264-6.
17. LAMBOTTE O, KOTB R, MAIGNE G et al.: Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005; 32: 1369-70.
18. BOHAN A, PETER JB: Polymyositis and dermatomyositis. N Engl J Med 1975; 292: 344-7.
19. TROYANOV Y, TARGOFF IN, TREMBLAY JL: Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and antibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005; 84: 231-49.
20. SULTAN SM, ISENBERG DA: Re-classifying Myositis. Rheumatology (Oxford) 2010; 49: 831-3.
21. SULTAN SM, NG KP, EDWARDS JC et al.: Clinical outcome following B cell depletion in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol 2008; 26: 887-93.
22. ISENBERG DA, ALLEN E, FAREWELL V et al.: International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004; 43: 49-54.
23. SULTAN SM, ALLEN E, ODDIS CV et al.: Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum 2008; 58: 3593-9.
24. RIDER LG, GIANNINI EH, HARRIS-LOVE M et al.: Defining clinical improvement in adult and juvenile myositis. J Rheumatol 2003; 30: 603-17.
25. ODDIS CV: Outcomes and disease activity measures for assessing treatments in the idiopathic inflammatory myopathies. Curr Rheumatol Rep 2005; 7: 87-93.
26. YAMASAKI Y, YAMADA H, YAMASAKI M et al.: Intravenous cyclophospamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007; 46: 124-30.
27. SEM M, MOLBERG O, LUND MB et al.: Rituximab treatment of the synthetase syndrome: a retrospective case series. Rheumatology (Oxford) 2009; 48: 968-71.
28. BRULHART L, WLADBURGER JM, GABAY C: Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 2006; 65: 974-5.
29. LEVINE TD: Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005; 52: 601-7.
30. CALLEJAS-RUBIO JL, CAMPS MT: Treatment with rituximab of autoimmune diseases: results from the AADEA's registry. Med Clin (Barc) 2008; 130: 79.
31. GOTTENBERG JE, GUILLEVIN L, LAMBOTTE O et al.: Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64: 913-20.
32. EDWARDS JC, CAMBRIDGE G: B cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006; 6: 394-403.
33. HENGSTMAN GJ, van den HOOGEN FH, van ENGELEN BG: Treatment of the inflammatory myopathies: update and practical recommendations. Expert Opin Pharmacother 2009; 10: 11831190.
34. TOURNADRE A, DUBOST JJ, SOUBRIER M: Treatment of inflammatory muscle disease in adults. Joint Bone Spine 2010; 77: 390-4.
35. COUDEREC M, GOTTENBERG JE, MARIETTE X et al.: Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from de AIR registry. Rheumatology (Oxford) 2011; 50: 2283-9.
36. MAHLER EA, BLOM M, VOERMANS NC et al.: Rituximab treatment in patients with refractory inflammatory myopthies. Rheumatology (Oxford) 2011; 50: 2206-13.
37. ODDIS CV, REED AM, AGGARWAL R et al.; RIM Study Group: Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial. Arthritis Rheum 2013; 65: 314-24.
38. RAMOS-CASALS M, GARCÍA-FERNÁNDEZ FJ, de RAMÓN E et al.: Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010; 28: 468-76.
39. EDWARDS JC, CAMBRIDGE G, LEANDRO MJ: B cell depletion in rheumatic disease. Best Pract Res Clin Rheumatol 2006; 20: 915-28.
40. REED AM, McNALLAN KT, ODDIS CV: Predictors of response to B cell depleting therapy in adult and juvenile myositis [abstract]. Arthritis Rheum 2010; 62 (Suppl. 10): 1379.
41. SULTAN SM: The assessment and importance of disease activity versus disease damage in patients with inflammatory myopathy. Curr Rheum Rep 2003; 5: 445-50.
42. ALEXANDERSON H, LUNDBERG E: Disease-specific quality indicators, outcome measures and guidelines in polymyositis and dermatomyositis. Clin Exp Rheumatol 2007; 25 (Suppl. 47): 153-8.